About   Help   FAQ
Phenotypes associated with this allele
Allele Symbol
Allele Name
Allele ID 		Bmp4tm2(tetO-Bmp4,lacZ)Jfm
targeted mutation 2, James F Martin
MGI:4941211
Summary 3 genotypes
Jump to Allelic Composition Genetic Background Genotype ID
hm1
 		Bmp4tm2(tetO-Bmp4,lacZ)Jfm/Bmp4tm2(tetO-Bmp4,lacZ)Jfm involves: 129S4/SvJaeSor MGI:5312876
cn2
 		Bmp4tm2(tetO-Bmp4,lacZ)Jfm/?
Gt(ROSA)26Sortm1(rtTA,EGFP)Nagy/?
Tg(Mef2c-cre)2Blk/? 		involves: 129S1/Sv * 129S4/SvJaeSor * 129X1/SvJ MGI:4941612
cn3
 		Bmp4tm2(tetO-Bmp4,lacZ)Jfm/Bmp4+
Gt(ROSA)26Sortm1(rtTA,EGFP)Nagy/Gt(ROSA)26Sor+
H2az2Tg(Wnt1-cre)11Rth/H2az2+ 		involves: 129/Sv * C57BL/6J * CBA/J MGI:5312862


Genotype
MGI:5312876
hm1
Allelic
Composition		 Bmp4tm2(tetO-Bmp4,lacZ)Jfm/Bmp4tm2(tetO-Bmp4,lacZ)Jfm
Genetic
Background		 involves: 129S4/SvJaeSor
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Bmp4tm2(tetO-Bmp4,lacZ)Jfm mutation (0 available); any Bmp4 mutation (21 available)
♀ phenotype observed in females
♂ phenotype observed in males
N normal phenotype
cardiovascular system
abnormal cardiac mesenchyme morphology ( J:181229 )
• reduction in mesenchymal cells in the outflow tract cushons at E10.5

embryo
abnormal head mesenchyme morphology ( J:181229 )
• reduction in mesenchymal cells in the medial cranial process at E10.5

growth/size/body
abnormal head mesenchyme morphology ( J:181229 )
• reduction in mesenchymal cells in the medial cranial process at E10.5




Genotype
MGI:4941612
cn2
Allelic
Composition		 Bmp4tm2(tetO-Bmp4,lacZ)Jfm/?
Gt(ROSA)26Sortm1(rtTA,EGFP)Nagy/?
Tg(Mef2c-cre)2Blk/?
Genetic
Background		 involves: 129S1/Sv * 129S4/SvJaeSor * 129X1/SvJ
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Bmp4tm2(tetO-Bmp4,lacZ)Jfm mutation (0 available); any Bmp4 mutation (21 available)
Gt(ROSA)26Sortm1(rtTA,EGFP)Nagy mutation (5 available); any Gt(ROSA)26Sor mutation (942 available)
Tg(Mef2c-cre)2Blk mutation (1 available)
♀ phenotype observed in females
♂ phenotype observed in males
N normal phenotype
cardiovascular system
thick myocardium ( J:169047 )
• in the right ventricle and out flow tract
abnormal heart right ventricle morphology ( J:169047 )
• thickening of the myocardium
abnormal heart ventricle outflow tract morphology ( J:169047 )
• thickening of the myocardium

muscle
thick myocardium ( J:169047 )
• in the right ventricle and out flow tract




Genotype
MGI:5312862
cn3
Allelic
Composition		 Bmp4tm2(tetO-Bmp4,lacZ)Jfm/Bmp4+
Gt(ROSA)26Sortm1(rtTA,EGFP)Nagy/Gt(ROSA)26Sor+
H2az2Tg(Wnt1-cre)11Rth/H2az2+
Genetic
Background		 involves: 129/Sv * C57BL/6J * CBA/J
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Bmp4tm2(tetO-Bmp4,lacZ)Jfm mutation (0 available); any Bmp4 mutation (21 available)
Gt(ROSA)26Sortm1(rtTA,EGFP)Nagy mutation (5 available); any Gt(ROSA)26Sor mutation (942 available)
H2az2Tg(Wnt1-cre)11Rth mutation (2 available); any H2az2 mutation (26 available)
♀ phenotype observed in females
♂ phenotype observed in males
N normal phenotype
craniofacial
abnormal craniofacial bone morphology ( J:181229 )
• following doxycycline treatment at E10.5 a strong reduction in rostral bony elements is seen and multiple translucent areas are seen in the skull bones
• later treatment with doxycycline has less dramatic effects on bone morphology
enlarged Meckel's cartilage ( J:181229 )
• enlarged following doxycycline treatment at E12.5
abnormal frontal bone morphology ( J:181229 )
• reduced or absent following doxycycline treatment at E12.5
absent frontal bone ( J:181229 )
• following doxycycline treatment at E12.5
small frontal bone ( J:181229 )
• following doxycycline treatment at E12.5
abnormal mandible morphology ( J:181229 )
• doxycycline treatment at E11.5 or E10.5 results in a shorter mandible with a more pointed appearance
• doxycycline treatment at E13.5 results in a mandible with a more pointed appearance
small mandibular coronoid process ( J:181229 )
• reduced following doxycycline treatment at E13.5
short mandible ( J:181229 )
• following doxycycline treatment at E12.5, E11.5 or at E10.5
abnormal maxilla morphology ( J:181229 )
• doxycycline treatment at E10.5 results in a shorter maxilla with a more pointed appearance
short maxilla ( J:181229 )
• following doxycycline treatment at E10.5
absent nasal bone ( J:181229 )
• following doxycycline treatment at E12.5 in some mice
small nasal bone ( J:181229 )
• following doxycycline treatment at E10.5, E12.5, or E13.5
short face ( J:181229 )
• shortened face following doxycycline treatment at E10.5
cleft palate ( J:181229 )
• following doxycycline treatment at E12.5
abnormal nasal cartilage morphology ( J:181229 )
• enlarged nasal cartilages following doxycycline treatment at E12.5 or E10.5
round head ( J:181229 )
• following doxycycline treatment at E10.5 the overall shape of the head is more rounded

vision/eye
abnormal eye distance/ position ( J:181229 )
• following doxycycline treatment at E10.5 the orientation of the eyes is more anterior

respiratory system
absent nasal bone ( J:181229 )
• following doxycycline treatment at E12.5 in some mice
small nasal bone ( J:181229 )
• following doxycycline treatment at E10.5, E12.5, or E13.5
abnormal nasal cartilage morphology ( J:181229 )
• enlarged nasal cartilages following doxycycline treatment at E12.5 or E10.5

digestive/alimentary system
cleft palate ( J:181229 )
• following doxycycline treatment at E12.5

skeleton
abnormal craniofacial bone morphology ( J:181229 )
• following doxycycline treatment at E10.5 a strong reduction in rostral bony elements is seen and multiple translucent areas are seen in the skull bones
• later treatment with doxycycline has less dramatic effects on bone morphology
enlarged Meckel's cartilage ( J:181229 )
• enlarged following doxycycline treatment at E12.5
abnormal frontal bone morphology ( J:181229 )
• reduced or absent following doxycycline treatment at E12.5
absent frontal bone ( J:181229 )
• following doxycycline treatment at E12.5
small frontal bone ( J:181229 )
• following doxycycline treatment at E12.5
abnormal mandible morphology ( J:181229 )
• doxycycline treatment at E11.5 or E10.5 results in a shorter mandible with a more pointed appearance
• doxycycline treatment at E13.5 results in a mandible with a more pointed appearance
small mandibular coronoid process ( J:181229 )
• reduced following doxycycline treatment at E13.5
short mandible ( J:181229 )
• following doxycycline treatment at E12.5, E11.5 or at E10.5
abnormal maxilla morphology ( J:181229 )
• doxycycline treatment at E10.5 results in a shorter maxilla with a more pointed appearance
short maxilla ( J:181229 )
• following doxycycline treatment at E10.5
absent nasal bone ( J:181229 )
• following doxycycline treatment at E12.5 in some mice
small nasal bone ( J:181229 )
• following doxycycline treatment at E10.5, E12.5, or E13.5
abnormal nasal cartilage morphology ( J:181229 )
• enlarged nasal cartilages following doxycycline treatment at E12.5 or E10.5

growth/size/body
absent nasal bone ( J:181229 )
• following doxycycline treatment at E12.5 in some mice
small nasal bone ( J:181229 )
• following doxycycline treatment at E10.5, E12.5, or E13.5
short face ( J:181229 )
• shortened face following doxycycline treatment at E10.5
cleft palate ( J:181229 )
• following doxycycline treatment at E12.5
abnormal nasal cartilage morphology ( J:181229 )
• enlarged nasal cartilages following doxycycline treatment at E12.5 or E10.5
round head ( J:181229 )
• following doxycycline treatment at E10.5 the overall shape of the head is more rounded




Contributing Projects:
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB)), Gene Ontology (GO)
Citing These Resources
Funding Information
Warranty Disclaimer, Privacy Notice, Licensing, & Copyright
Send questions and comments to User Support. 		last database update
04/16/2024
MGI 6.23 		The Jackson Laboratory